journal article·2020-02Open access

A novel GSH responsive poly(alpha-lipoic acid) nanocarrier bonding with the honokiol-DMXAA conjugate for combination therapy

Zhilin Liu, Zhaohui Tang, Dawei Zhang, Jiatan Wu, Xinghui Si, Na Shen, Xuesi Chen

Science China Materials· Volume 63· Issue 2

Abstract

The key to improve the therapeutic efficacy for cancer treatment is to increase the delivery of drugs to tumors. For this purpose, tumor-microenvironment stimuli- responsive materials have great potential. Here, we prepared a new nanomedicine by bonding the conjugate of honokiol (HNK) and 5,6-dimethylxanthenone-4-acetic acid (DMXAA) to a glutathione (GSH)-responsive nanocarrier, poly( α -lipoic acid) polyethylene glycol. The nanomedicine would disintegrate due to the high level of GSH at the tumor sites, achieving the co-delivery of HNK and DMXAA, and realizing the combination therapy through close-range killing by HNK and long-range striking by DMXAA together. In a murine 4T1 breast tumor model, this strategy exhibited high tumor inhibition rate of 93%, and provided a valuable therapeutic choice for cancer therapy.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Biochemical Acid Research Studies · Macrophage Migration Inhibitory Factor · Histone Deacetylase Inhibitors Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (29)

Show source-provided references
1. Chen H, Gu Z, An H, et al. Precise nanomedicine for intelligent therapy of cancer. Sci China Chem, 2018, 61: 1503–155210.1007/s11426-018-9397-5 ↗
2. Chen J, Lin L, Yan N, et al. Macrophages loaded CpG and GNR-PEI for combination of tumor photothermal therapy and immunotherapy. Sci China Mater, 2018, 61: 1484–149410.1007/s40843-018-9238-6 ↗
3. Hasani A, Leighl N. Classification and toxicities of vascular disrupting agents. Clin Lung Cancer, 2011, 12: 18–2510.3816/CLC.2011.n.002 ↗
4. Daei Farshchi Adli A, Jahanban-Esfahlan R, Seidi K, et al. An overview on vadimezan (DMXAA): the vascular disrupting agent. Chem Biol Drug Des, 2018, 91: 996–100610.1111/cbdd.13166 ↗
5. Bähr O, Gross S, Harter P, et al. ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors. Oncol Lett, 2017, 14: 5443–5451
6. Hohenberger P, Elleni S, Marc F, et al. Vascular disrupting agent ASA 404 evaluated in human isolated ventilated and perfused lung lobes containing NSCLC. Eur J Cancer, 2015, 51: S60810.1016/S0959-8049(16)31678-1 ↗
7. Lv S, Tang Z, Song W, et al. Inhibiting solid tumor growth in vivo by non-tumor-penetrating nanomedicine. Small, 2017, 13: 160095410.1002/smll.201600954 ↗
8. Song W, Tang Z, Zhang D, et al. Solid tumor therapy using a cannon and pawn combination strategy. Theranostics, 2016, 6: 1023–103010.7150/thno.14741 ↗
9. Cheng R, Meng F, Deng C, et al. Bioresponsive polymeric nanotherapeutics for targeted cancer chemotherapy. Nano Today, 2015, 10: 656–67010.1016/j.nantod.2015.09.005 ↗
10. Cheng R, Meng F, Deng C, et al. Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. Biomaterials, 2013, 34: 3647–365710.1016/j.biomaterials.2013.01.084 ↗
11. Ganta S, Devalapally H, Shahiwala A, et al. A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release, 2008, 126: 187–20410.1016/j.jconrel.2007.12.017 ↗
12. Thornton P, Mart R, Ulijn R. Enzyme-responsive polymer hydrogel particles for controlled release. Adv Mater, 2007, 19: 1252–125610.1002/adma.200601784 ↗
13. Chen K, Liao S, Guo S, et al. Enzyme/pH-sensitive dendritic polymer-DOX conjugate for cancer treatment. Sci China Mater, 2018, 61: 1462–147410.1007/s40843-018-9277-8 ↗
14. Du JZ, Du XJ, Mao CQ, et al. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. J Am Chem Soc, 2011, 133: 17560–1756310.1021/ja207150n ↗
15. Du JZ, Sun TM, Song WJ, et al. A tumor-acidity-activated charge-conversional nanogel as an intelligent vehicle for promoted tumoral-cell uptake and drug delivery. Angew Chem Int Ed, 2010, 49: 3621–362610.1002/anie.200907210 ↗
16. Xu Q, He C, Xiao C, et al. Reactive oxygen species (ROS) responsive polymers for biomedical applications. Macromol Biosci, 2016, 16: 635–64610.1002/mabi.201500440 ↗
17. Yuan F, Li JL, Cheng H, et al. A redox-responsive mesoporous silica based nanoplatform for in vitro tumor-specific fluorescence imaging and enhanced photodynamic therapy. Biomater Sci, 2017, 6: 96–10010.1039/C7BM00793K ↗
18. Chen D, Zhang G, Li R, et al. Biodegradable, hydrogen peroxide, and glutathione dual responsive nanoparticles for potential programmable paclitaxel release. J Am Chem Soc, 2018, 140: 7373–737610.1021/jacs.7b12025 ↗
19. Elzes MR, Akeroyd N, Engbersen JFJ, et al. Disulfide-functional poly(amido amine)s with tunable degradability for gene delivery. J Control Release, 2016, 244: 357–36510.1016/j.jconrel.2016.08.021 ↗
20. Zhang P, Wu J, Xiao F, et al. Disulfide bond based polymeric drug carriers for cancer chemotherapy and relevant redox environments in mammals. Med Res Rev, 2018, 38: 1485–151010.1002/med.21485 ↗
21. Perry RR, Mazetta J, Levin M, et al. Glutathione levels and variability in breast tumors and normal tissue. Cancer, 1993, 72: 783–78710.1002/1097-0142(19930801)72:3<783::AID-CNCR2820720325>3.0.CO;2-U ↗
22. Huang ZZ, Chen C, Zeng Z, et al. Mechanism and significance of increased glutathione level in human hepatocellular carcinoma and liver regeneration. Faseb J, 2001, 15: 19–2110.1096/fj.00-0445fje ↗
23. Wolf CR, Lewis AD, Carmichael J, et al. The role of glutathione in determining the response of normal and tumour cells to anticancer drugs. Biochm Soc Trans, 1987, 15: 728–73010.1042/bst0150728 ↗
24. Schnelldorfer T, Gansauge S, Gansauge F, et al. Glutathione depletion causes cell growth inhibition and enhanced apoptosis in pancreatic cancer cells. Cancer, 2000, 89: 1440–144710.1002/1097-0142(20001001)89:7<1440::AID-CNCR5>3.0.CO;2-0 ↗
25. Lee MH, Yang Z, Lim CW, et al. Disulfide-cleavage-triggered chemosensors and their biological applications. Chem Rev, 2013, 113: 5071–510910.1021/cr300358b ↗
26. Nie JJ, Qiao B, Duan S, et al. Unlockable nanocomplexes with self-accelerating nucleic acid release for effective staged gene therapy of cardiovascular diseases. Adv Mater, 2018, 30: 180157010.1002/adma.201801570 ↗
27. Liu Z, Shen N, Tang Z, et al. An eximious and affordable GSH stimulus-responsive poly(α-lipoic acid) nanocarrier bonding combretastatin A4 for tumor therapy. Biomater Sci, 2019, 7: 2803–281110.1039/C9BM00002J ↗
28. Kisanuki A, Kimpara Y, Oikado Y, et al. Ring-opening polymerization of lipoic acid and characterization of the polymer. J Polym Sci A Polym Chem, 2010, 48: 5247–525310.1002/pola.24325 ↗
29. Ishida H, Kisanuki A, Endo K. Ring-opening polymerization of aromatic 6-membered cyclic disulfide and characterization of the polymer. Polym J, 2009, 41: 110–11710.1295/polymj.PJ2008219 ↗